All In Biotech

Drug Trial Radar · NCT06789913

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 277 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

277

Planned (sponsor's estimate)

Start

Jun 13, 2025

Primary completion

Jul 2031

Study completion Oct 2031

Sponsor

Lead sponsor
Relay Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, zovegalisib (RLY-2608), in adults and children with PIK3CA Related Overgrowth Spectrum (PROS) and malformations driven by PIK3CA mutation. Part 1 is a dose selection, Part 2 is a basket design with exploratory single-arm cohorts for various subpopulations of participants, and Part 3 is randomized, double-blinded study vs placebo.

Conditions

  • PIK3CA-Related Overgrowth Spectrum (PROS)
  • Lymphatic Malformations
  • Vascular Malformations
  • PIK3CA Mutation
  • CLOVES Syndrome
  • Klippel Trenaunay Syndrome
  • Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)
  • Vascular Anomalies

Interventions

  • RLY-2608Drug

    RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.

  • PlaceboDrug

    RLY-2608 matched-placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts 1 and 2: Determination of a recommended phase 2 dose RP2D(s) for Groups 1, 2, and 3Time frame: Cycle 1 of treatment and at the end of every cycle until study discontinuation
  2. Parts 1 and 2: Occurrence/frequency of Adverse Events (AEs), changes in vital signs, ECGs, and safety laboratory tests and their relationship to the study drugs (safety and tolerability).Time frame: Cycle 1 of treatment and at the end of every cycle until study discontinuation
  3. Part 3: Percentage of participants with volumetric Response.Time frame: Baseline, Week 24

Locations

49 sites in 10 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona · Recruiting

  • Arkansas Children's Hospital

    Little Rock, Arkansas · Recruiting

  • University of California, Los Angeles

    Los Angeles, California · Recruiting

  • Stanford University

    Palo Alto, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • Children's Hospital Colorado

    Aurora, Colorado · Recruiting

  • Children's Hospital of Atlanta

    Atlanta, Georgia · Recruiting

  • Riley Children's Hospital

    Indianapolis, Indiana · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • Johns Hopkins Medical Institute

    Baltimore, Maryland · Recruiting

  • Boston Children's Hospital

    Boston, Massachusetts · Recruiting

  • Corewell Health

    Grand Rapids, Michigan · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • University of Missouri

    Columbia, Missouri · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • UNC Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • Cleveland Clinic Children's

    Cleveland, Ohio · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Texas Children's Hospital

    Houston, Texas · Recruiting

  • University of Texas Health Center - Houston

    Houston, Texas · Recruiting

  • Seattle Children's Hospital

    Seattle, Washington · Recruiting

  • University of Wisconsin, Madison

    Madison, Wisconsin · Recruiting

  • The Skin Hospital

    Sydney, Australia · Recruiting

  • Sydney Children's Hospital at Westmead

    Westmead, Australia · Recruiting

  • Sydney Children's Hospital, Randwick

    Randwick, New South Wales, Australia · Recruiting

  • Children's Health Queensland Hospital and Health

    South Brisbane, Queensland, Australia · Recruiting

  • Monash Health

    Clayton, Victoria, Australia · Recruiting

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia · Recruiting

  • Murdoch Children's Research Institute

    Parkville, Victoria, Australia · Recruiting

  • UC Louvain

    Brussels, Belgium · Recruiting

  • CHU Amiens

    Amiens, France · Recruiting

  • CHU de Bordeaux

    Bordeaux, France · Recruiting

  • CHU Dijon

    Dijon, France · Recruiting

  • Hôpital de la Timone

    Marseille, France · Recruiting

  • Necker Hospital

    Paris, France · Recruiting

  • University of Halle

    Halle, Germany · Recruiting

  • Children's Health Ireland at Crumlin

    Dublin, Ireland · Recruiting

  • Ospedale Maggiore Policlinico

    Milan, Italy · Recruiting

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.